Ronald J. Graf, MD joined MultiCare Health System in December of 2009. He has been conducting research in Pierce County since 1978. Dr. Graf is a highly regarded endocrinologist and researcher and he has an excellent rapport with his patients.
Because of his success as a Principal Investigator, sponsors often request his site for their clinical trials. Two of our MultiCare Internal Medicine Specialists have joined Dr. Graf as co-investigators. Dr. Graf has conducted clinical trials in a wide variety of therapeutic areas including:
Our Endocrinology and General Medicine Investigators include:
Ronald J. Graf, MD, FAACE (Principal Investigator)
Daniel C. Ginsberg, MD, FACP (Co-Investigator)
Bradley J. Schmitz, MD (Co-Investigator)
Kletter, B. Gadi, MD (Principal Investigator, Pediatric)
The MultiCare Institute for Research & Innovation (MIRI) is partnering with TrialNet to offer risk screening, free of charge, to relatives of people with type I diabetes (T1D). With a simple blood test, TrialNet looks for autoantibodies that can predict risk of developing the disease, and identify the early stages of T1D, sometimes years before symptoms appear. Risk screening also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.
Who can be screened?
• Anyone between the ages of 1 and 45 with a sibling, child or parent with type 1 diabetes.
• Anyone between the ages of 1 and 20 with a sibling, child, parent, cousin, uncle, aunt, niece, nephew, grandparent or half-sibling with type 1 diabetes.
What is risk screening?
A free blood test can identify five autoantibodies that signal an increased risk of type 1 diabetes (T1D). These autoantibodies may show up years before symptoms appear.
• Family members of those with type 1 diabetes have a 15 times greater risk of developing the disease.
• TrialNet screening reveals if you are in the early stages of type 1 diabetes.
Be proactive with your health! Join us!
Sign up for screening today.
Study Number: D169AC00001 - A study to Evaluate the Effect of Dapagilflozin on Renal Outcomes and CArdiovascualr Mortality in Patients with Chronic Kidney Disease.
Principal Investigator(s): Ronald Graf, MD
Study Coordinator: Denise Quinn, [email protected], 253-301-6991
Study Number: GL-GLAT1-3001 - Open-label, randomized, multicenter, phase 3 study to compare the immunogenicity, efficacy, and safety of Gan & Lee Pharmaceuticals insulin glargine injection to Lantus (insulin glargine injection) in adult subjects with Type 1 diabetes mellitus.